Sign inJoin waitlistJoin the waitlist

Candace Haddox

Physician · Mass General Brigham

Credentials: · · · · ·

History

Dana-Farber Cancer Institute
2021–Present

Duke University Hospital
2018–2020
Internal Medicine
Mayo Clinic
2015–2018
USF Health Morsani College of Medicine
2011–2015

Research

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Review · Journal of Oncology Practice · 2018 · 362 citations
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Cancer Discovery · 2023 · 199 citations
Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
BMJ Open Diabetes Research & Care · 2019 · 185 citations

Elizabeth Baldini
4 papers
Richard Riedel
4 papers
Suzanne George
4 papers
Andrew Wagner
3 papers
David Papke
3 papers
Evanthia Galanis
3 papers
Jason Hornick
3 papers
Jonas Paludo
3 papers
Priscilla Merriam
3 papers
VV
Vinayak Venkataraman
3 papers · 1 as a fellow
Chandrajit Raut
2 papers
Edwin Choy
2 papers

Clinical trials

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Principal investigator · Active not recruiting · Phase 2
Sarcoma Alliance for Research through Collaboration
2024–2027
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2026
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2027